impact factor

Targeted systemic DMARDs in psoriatic arthritis


Apremilast in psoriatic arthritis



  1. Department of Internal Medicine 3, University of Erlangen-Nuremberg Erlangen, Germany.

2015 Vol.33, N°5 ,Suppl.93
PI 0098, PF 0100
Targeted systemic DMARDs in psoriatic arthritis

Free to view
(click on article PDF icon to read the article)

PMID: 26472278 [PubMed]

Received: 26/09/2015
Accepted : 27/09/2015
In Press: 15/10/2015
Published: 16/10/2015


Apremilast is a small molecule inhibitor of phosphodiesterase (PDE) 4 approved for the treatment of psoriatic arthritis (PsA). The efficacy and safety of apremilast in PsA have been demonstrated in four phase III trials. The compound has been approved for the treatment of moderate to severe PsA in the United States and in Europe. Apremilast also shows efficacy in psoriatic skin disease. Its mode of action is based on an increase of immune-regulatory cAMP in immune cells, which is mediated through the inhibition of the cAMP-degrading enzyme PDE4. Higher levels of cAMP inhibit cytokines involved in the pathogenesis of psoriasis, such as TNF-alpha or IL-23, resulting in clinical improvement.

Rheumatology Article